Joel David Sendek
CFO & Principal Financial OfficerMr. Joel David Sendek has been Chief Financial Officer of Perspective Therapeutics, Inc. since September 4, 2025 and serves as its Principal Financial Officer. He serves as Managing Director and Head of Life Sciences Equity Research at Oppenheimer & Co. Inc., Research Division since September 2022. Earlier, he served as Chief Financial Officer and Treasurer at Dewpoint Therapeutics, Inc. since February 2021 until July 2022. Prior to that, Mr. Sendek served as Chief Financial Officer at Sema4, where he facilitated the company's Series C financing. He served as Chief Financial Officer at Spero Therapeutics, Inc. since May 22, 2017 until November 8, 2019, where he guided company through an initial public offering. Mr. Sendek was Treasurer at Spero Therapeutics until November 8, 2019. Mr. Sendek served as Treasurer and Secretary at Spero Therapeutics until September 30, 2019. Mr. Sendek served as Chief Financial Officer at Forward Pharma A/S from August 5, 2014 to April 30, 2017, where he guided company through an initial public offering and as a Senior Equity Research Analyst covering biotechnology from 1997 to 2014. Earlier, Mr. Sendek served as the Managing Director at Stifel, Nicolaus & Company, Incorporated, Research Division and served as its Biotechnology Analyst since 2012. Mr. Sendek spent many years as a Senior Equity Research Analyst covering biotech and leading healthcare equity research as Managing Director at Stifel Financial Corp. He served as the Managing Director and Biotechnology Analyst at Lazard Capital Markets LLC, Research Division, where he established firm’s healthcare equity research effort in 2000. He served as Senior Vice President and Biotechnology Research Analyst at Gerard Klauer Mattison and served as an Equity Analyst at BMO Capital Markets U.S. Prior to equity research, Mr. Sendek worked in business development at Progenics Pharmaceuticals and as an investment banker at Goldman Sachs. From 1992 to 1997, he served as Senior Director of Corporate Development at Progenics Pharmaceuticals. Prior to Progenics, Mr. Sendek worked in the corporate finance department and Investment Banking Analyst at Goldman, Sachs & Co., focused on healthcare, from 1989 to 1992. He was a Managing Director at Lazard Ltd. since January 2000. Mr. Sendek received a Bachelor of Arts in Biochemistry from Rice University in 1989.
Positions
- Company NamePerspective Therapeutics, Inc.Stock CodeCATXPositionCFO & Principal Financial OfficerColleagues
- JMJohan M. SpoorCEO & Director
- LALori A. Holmes-WoodsChairperson of the Board
- MPMarkus PuhlmannChief Medical Officer
- MKMichael K. SchultzCo-Founder & Senior Scientific Advisor
- SCShane CobbExecutive Vice President of Operations
- RFRobert Froman WilliamsonIndependent Director
- FMFrank MorichIndependent Director
- HHHeidi HensonIndependent Director
